Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1753-1764

  Sacco, Antonio ^a,b   Aujay, Monette ^c   Morgan, Brittany ^a,b   Azab, Abdel Kareem ^a,b   Maiso, Patricia ^a,b   Liu, Yang ^a,b   Zhang, Yong ^a,b   Azab, Feda ^a,b   Ngo, Hai T ^a,b   Issa, Ghayas C ^a,b   Quang, Phong ^a,b   Roccaro, Aldo M ^a,b   Ghobrial, Irene M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CASPASE; CHYMOTRYPSIN; GLUCOSE REGULATED PROTEIN 94; IMMUNOGLOBULIN M; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; UNFOLDED PROTEIN RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; BORONIC ACIDS; CASPASES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINE CXCL12; CHYMOTRYPSIN; COCULTURE TECHNIQUES; DNA FRAGMENTATION; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYMPHOMA; MICE; MICE, SCID; OLIGOPEPTIDES; POLY(ADP-RIBOSE) POLYMERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SERINE PROTEINASE INHIBITORS; UNFOLDED PROTEIN RESPONSE; WALDENSTROM MACROGLOBULINEMIA;

EID: 79953300497     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2130     Document Type: Article

References (26)

1. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood 2007;109:5096-103.
2. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003;4:679-85.
3. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:110-5. (Pubitemid 36506291)
4. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29:3-9. (Pubitemid 36626287)
5. Glynne R, Powis SH, Beck S, Kelly A, Kerr LA, Trowsdale J, et al. (A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 1991;353:357-60.
6. Martinez CK, Monaco JJ.Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene. Nature 1991;353:664-7. (Pubitemid 21912585)
7. Nandi D, Jiang H, Monaco JJ. Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J.Immunol 1996;156:2361-4. (Pubitemid 26091557)
8. Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009;114: 3439-47.
9. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90. (Pubitemid 350106321)
10. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91. (Pubitemid 47037522)
11. Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010; 115:559-69.
12. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008;111:4752-63.
13. Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010;115:4051-60.
14. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16. (Pubitemid 43882644)
15. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, et al. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2009;113:626-34.
16. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42:1564-73. (Pubitemid 44118771)
17. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, Sherman MY. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998;273:6373-9. (Pubitemid 28144729)
18. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109: 2708-17. (Pubitemid 46482062)
19. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, etal.Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009;52:3028-38.
20. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008;111:1654-64. (Pubitemid 351213457)
21. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of Bortezomib in relapsed/refractory Waldenstrom's Macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res 2007;13:3320-5. (Pubitemid 46944918)
22. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-8.
23. O'Connor OA, Stewart KA, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, et al. A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91.
24. Jagannath S, Vij R, Stewart K, Sombo G, Jakubowiak A, Trudel S, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM) [abstaract]. J Clin Oncol 2009;27:15s. Abstract 8504.
25. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009;113:4667-76.
26. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107: 4907-16. (Pubitemid 43882644)